ImageneBio, Inc. (NASDAQ:IMA) Shares Shorted: Short Interest Up 86.7% in October

ImageneBio, Inc. (NASDAQ:IMA) saw a significant growth in short interest in October. As of October 15th, there was short interest totaling 61,349 shares, a growth of 86.7% from the September 30th total of 32,852 shares. Based on an average daily volume of 14,638 shares, the short-interest ratio is presently 4.2 days. Approximately 0.6% of the company’s shares are sold short.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. HC Wainwright started coverage on shares of ImageneBio in a report on Friday, August 21st. They issued a “buy” rating and a $28.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a report on Friday, September 25th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $28.00.

Hedge Funds Weigh In On ImageneBio

Institutional investors have recently added to or reduced their stakes in the company. Rangeley Capital LLC grew its position in shares of ImageneBio by 78.6% during the 1st quarter. Rangeley Capital LLC now owns 32,590 shares of the company’s stock valued at $163,000 after buying an additional 14,346 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in ImageneBio by 23.6% in the first quarter. Renaissance Technologies LLC now owns 81,696 shares of the company’s stock worth $408,000 after purchasing an additional 15,600 shares during the period. BML Capital Management LLC increased its stake in ImageneBio by 13.4% during the 1st quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock valued at $1,004,000 after buying an additional 23,704 shares during the period. Hsbc Holdings PLC acquired a new position in ImageneBio during the 2nd quarter valued at about $208,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of ImageneBio during the 2nd quarter worth about $539,044,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Trading Down 0.2%

Shares of NASDAQ IMA opened at $4.09 on Tuesday. The company’s 50-day moving average price is $4.64 and its 200 day moving average price is $5.63. ImageneBio has a 52 week low of $3.88 and a 52 week high of $8.84. The stock has a market cap of $46.43 million, a price-to-earnings ratio of -0.89 and a beta of 0.74.

ImageneBio (NASDAQ:IMA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.27. As a group, research analysts expect that ImageneBio will post -3.23 earnings per share for the current year.

About ImageneBio

ImageneBio, Inc is a biotechnology company focused on advancing precision oncology through blood-based molecular testing and data analysis. The company develops technologies designed to help identify and monitor cancer-related genomic signals using liquid biopsy samples.

Its platform is intended to support the detection and tracking of tumor biomarkers, potentially helping clinicians assess treatment response, identify disease progression, and guide more personalized cancer-care decisions.